1. Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration.
- Author
-
Croteau D, Best BM, Letendre S, Rossi SS, Ellis RJ, Clifford DB, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, and Grant I
- Subjects
- Adult, CCR5 Receptor Antagonists, Chromatography, Reverse-Phase, Cross-Sectional Studies, Cyclohexanes blood, Cyclohexanes therapeutic use, Female, HIV Infections blood, HIV Infections drug therapy, Humans, Inhibitory Concentration 50, Male, Maraviroc, Middle Aged, RNA, Viral blood, Tandem Mass Spectrometry, Triazoles blood, Triazoles therapeutic use, Cyclohexanes cerebrospinal fluid, HIV Infections cerebrospinal fluid, HIV-1, Triazoles cerebrospinal fluid
- Abstract
To measure maraviroc total cerebrospinal fluid (CSF) concentrations and compare them with total and unbound plasma concentrations. Total maraviroc was measured by reverse-phase high-performance liquid chromatography with tandem mass spectrometry, whereas ultrafiltration was used for unbound maraviroc. Maraviroc was detected in all nine CSF/plasma pairs with a median CSF total concentration of 2.4 ng/ml. CSF concentrations exceeded the 50% inhibitory concentration of wild-type CC chemokine receptor 5-tropic HIV-1 in all specimens. CSF concentrations are lower than expected based on plasma concentrations and physicochemical characteristics. Unbound maraviroc plasma concentrations may be informative in estimating concentrations in CSF.
- Published
- 2012
- Full Text
- View/download PDF